89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH
September 13 2020 - 7:53PM
89bio, Inc. (Nasdaq: ETNB) today announced that the company plans
to share topline safety, tolerability and efficacy data from its
Phase 1b/2a study of BIO89-100 in NASH in a pre-market press
release and webcast to be held on Monday, September 14, 2020.
Conference Call/Webcast DetailsThe
company will host a conference call and webcast with slides at
8:30am PT (5:30am PT) tomorrow morning, September 14. Details for
the live conference call are as follows: Domestic – (833) 570-1145;
International – (914) 987-7092; and Passcode - 5064866. To access
the live webcast and slides, please visit “Events and
Presentations” under the “Investors” section of 89bio’s website at
https://ir.89bio.com/events-and-presentations. Following the live
audio webcast, a replay will be available on the company’s website
for 90 days.
About 89bio 89bio is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
liver and cardio-metabolic diseases. The company's lead product
candidate, BIO89-100, is a specifically engineered glycoPEGylated
analog of FGF21. BIO89-100 is being developed for the treatment of
NASH and severe hypertriglyceridemia (SHTG). 89bio is headquartered
in San Francisco with operations in Herzliya, Israel. For more
information, visit www.89bio.com.
Investor Contact: Ryan Martins Chief Financial
Officer investors@89bio.com
Media Contact: Lori Rosen LDR Communications
917-553-6808 lori@ldrcommunications.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2023 to Apr 2024